We are live on ! Find out more
NVET

Nexvet Biopharma plc Ordinary Shares
NVET

Delisted

NVET was delisted on the 28th of July, 2017.

Back to rankings

15 hedge funds and large institutions have $26.7M invested in Nexvet Biopharma plc Ordinary Shares in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more capital invested

Capital invested by funds: $18.9M → $26.7M (+$7.76M)

17% less funds holding

Funds holding: 18 → 15 (-3)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.4%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
2
Increased
1
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LLC
Latimer Light Capital
New York
+$130K
2
FCMI
Foresite Capital Management II
California
+$42.9K

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$105K
2
Bank of America
Bank of America
North Carolina
-$10.8K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$6.33K
4
UBS Group
UBS Group
Switzerland
-$4K
5
TRCT
Tower Research Capital (TRC)
New York
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$12.3M – – –
BC
2
Broadfin Capital
New York
$4.64M – – –
FCMI
3
Foresite Capital Management II
California
$4.18M +$42.9K +12,354 +1%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$4.06M – – –
BC
5
Boxer Capital
California
$720K – – –
BCM
6
Bridgeway Capital Management
Texas
$206K – – –
LLC
7
Latimer Light Capital
New York
$173K +$130K +37,301 New
Norges Bank
8
Norges Bank
Norway
$164K – – –
CI
9
Cowen Inc
New York
$128K – – –
Bank of America
10
Bank of America
North Carolina
$56K -$10.8K -3,100 -20%
Citigroup
11
Citigroup
New York
$27K – – –
Morgan Stanley
12
Morgan Stanley
New York
$18K – – –
Deutsche Bank
13
Deutsche Bank
Germany
$5K – – –
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$3K -$6.33K -1,821 -76%
PAM
15
Panagora Asset Management
Massachusetts
– -$105K -31,741 Closed
UBS Group
16
UBS Group
Switzerland
– -$4K -1,354 Closed
TRCT
17
Tower Research Capital (TRC)
New York
– -$3K -795 Closed
AG
18
Advisor Group
Arizona
– +$313 +90 New

NVET Hedge Fund Activity: Q2 2016 in Review

15 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q2 2016, worth a combined $26.7M — up 41% from $18.9M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NVET and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Latimer Light Capital, opening a new position worth an estimated $130K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $105K sold.

  • 15 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q2 2016, down from 18 in Q1 2016.
  • Funds reported $26.7M of Nexvet Biopharma plc Ordinary Shares stock for Q2 2016, up 41% quarter-over-quarter.
  • 2 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q2 2016 and 5 closed out, a net change of -3 holders.
  • The largest Nexvet Biopharma plc Ordinary Shares buyer in Q2 2016 was Latimer Light Capital, an estimated $130K added.
  • The largest Nexvet Biopharma plc Ordinary Shares seller in Q2 2016 was Panagora Asset Management, an estimated $105K sold.

Based on aggregated 13F filings for Q2 2016.